Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors, Advanced Breast Cancer
In brief
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Key facts
- Study ID
- NCT06993844
- Run by
- Ensem Therapeutics
- People needed
- 233
- Starts
- 2025-06-10
- Expected to finish
- 2027-12-30
- Last updated by the study team
- 2026-06-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fujian Cancer Hospital — Fuzhou, China (enrolling)
- Sun Yat-sen University Cancer Center — Guangzhou, China (enrolling)
- Shandong Cancer Hospital&Institute — Shandong, China (enrolling)
- Fudan University Shanghai Cancer Hospital — Shanghai, China (enrolling)
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States (enrolling)
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (enrolling)
- Yale University, Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Carolina BioOncology Institute — Huntersville, North Carolina, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- START — San Antonio, Texas, United States (enrolling)
- NEXT — Fairfax, Virginia, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- Beijing Luhe Hospital,Capital Medical University — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.